Matt O'Brien
Stock Analyst at Piper Sandler
(2.19)
# 2,902
Out of 5,041 analysts
187
Total ratings
42.58%
Success rate
-4.94%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Maintains: Overweight | $155 → $82 | $72.91 | +12.47% | 3 | Oct 24, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $30 → $22 | $17.03 | +29.18% | 3 | Oct 10, 2025 | |
| SI Shoulder Innovations | Initiates: Overweight | $18 | $12.30 | +46.34% | 1 | Aug 25, 2025 | |
| CARL Carlsmed | Initiates: Overweight | $18 | $13.46 | +33.73% | 1 | Aug 18, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $80 → $55 | $34.99 | +57.19% | 4 | Aug 7, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Neutral | $30 → $14 | $14.95 | -6.35% | 9 | Aug 7, 2025 | |
| DXCM DexCom | Maintains: Overweight | $90 → $100 | $70.33 | +42.19% | 12 | Jul 31, 2025 | |
| CNMD CONMED | Maintains: Overweight | $80 → $68 | $47.76 | +42.38% | 13 | Jul 31, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $130.52 | +11.09% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $62.29 | +28.43% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $10.45 | +14.83% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $15 | $16.11 | -6.89% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $74.67 | +120.97% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $26.00 | +3.85% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $2 | $1.47 | +35.78% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $5.28 | -33.65% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $131.91 | +6.13% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $20.97 | +23.99% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $320.91 | -3.40% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $252.99 | +30.44% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $37.54 | +33.19% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $26.27 | -39.09% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $101.11 | +13.74% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.97 | +202.27% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $381.79 | +10.01% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $93.67 | -3.92% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $15.49 | +61.39% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.71 | +75.44% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.21 | +40.19% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $103.03 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $3.96 | +278.79% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $73.51 | +47.94% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $1.40 | +1,198.57% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $23.02 | +247.52% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.23 | +183.69% | 1 | Jun 24, 2020 |
Integer Holdings
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $72.91
Upside: +12.47%
OrthoPediatrics
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $17.03
Upside: +29.18%
Shoulder Innovations
Aug 25, 2025
Initiates: Overweight
Price Target: $18
Current: $12.30
Upside: +46.34%
Carlsmed
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $13.46
Upside: +33.73%
PROCEPT BioRobotics
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $55
Current: $34.99
Upside: +57.19%
Tandem Diabetes Care
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $14.95
Upside: -6.35%
DexCom
Jul 31, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $70.33
Upside: +42.19%
CONMED
Jul 31, 2025
Maintains: Overweight
Price Target: $80 → $68
Current: $47.76
Upside: +42.38%
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $130.52
Upside: +11.09%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $62.29
Upside: +28.43%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $10.45
Upside: +14.83%
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $16.11
Upside: -6.89%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $74.67
Upside: +120.97%
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $26.00
Upside: +3.85%
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.47
Upside: +35.78%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $5.28
Upside: -33.65%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $131.91
Upside: +6.13%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $20.97
Upside: +23.99%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $320.91
Upside: -3.40%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $252.99
Upside: +30.44%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $37.54
Upside: +33.19%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $26.27
Upside: -39.09%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $101.11
Upside: +13.74%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.97
Upside: +202.27%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $381.79
Upside: +10.01%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $93.67
Upside: -3.92%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $15.49
Upside: +61.39%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.71
Upside: +75.44%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.21
Upside: +40.19%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $103.03
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $3.96
Upside: +278.79%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $73.51
Upside: +47.94%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $1.40
Upside: +1,198.57%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $23.02
Upside: +247.52%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.23
Upside: +183.69%